View Older Stories View More Recent Stories

Feb 10, 2022 04:00PM Cytokinetics to Announce Fourth Quarter Results on February 24, 2022
Feb 4, 2022 07:30AM Cytokinetics (CYTK) Announces FDA Acceptance of NDA for Omecamtiv Mecarbil for the Treatment of Heart Failure With Reduced Ejection Fraction
Feb 4, 2022 07:30AM Cytokinetics Announces FDA Acceptance of New Drug Application for Omecamtiv Mecarbil for the Treatment of Heart Failure With Reduced Ejection Fraction
Feb 1, 2022 04:00PM Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Feb 1, 2022 07:31AM Cytokinetics (CYTK) Announces Positive Topline Results from Cohort 3 of REDWOOD-HCM
Feb 1, 2022 07:30AM Cytokinetics Announces Positive Topline Results from Cohort 3 of REDWOOD-HCM
Jan 24, 2022 07:30AM Cytokinetics Announces Recipients of Fourth Annual Communications Fellowship Grants
Jan 10, 2022 05:00PM Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jan 7, 2022 07:31AM Cytokinetics (CYTK) and Royalty Pharma (RPRX) Announce Funding Agreements Totaling up to $450 Million
Jan 7, 2022 07:30AM Cytokinetics and Royalty Pharma Announce Funding Agreements Totaling up to $450 Million
Jan 3, 2022 04:00PM Cytokinetics to Participate in the 40th Annual J.P. Morgan Healthcare Conference
Dec 20, 2021 07:32AM Cytokinetics (CYTK) Expands Collaboration with JI XING to Include Licensing of Omecamtiv Mecarbil in China
Dec 20, 2021 07:30AM Cytokinetics and JI XING Announce Expansion of Collaboration to Include Licensing of Omecamtiv Mecarbil in China; RTW to Add to Its Investment in Cytokinetics
Dec 10, 2021 07:31AM Cytokinetics (CYTK) Reports Data From Its ALS Program
Dec 10, 2021 07:30AM Cytokinetics Announces Data From Its ALS Program Presented at the 32nd International Symposium on ALS/MND
Dec 9, 2021 07:31AM Cytokinetics (CYTK) Receives Breakthrough Therapy Designation from FDA for Aficamten
Dec 9, 2021 07:30AM Cytokinetics Announces Receipt of Breakthrough Therapy Designation from FDA for Aficamten
Dec 1, 2021 04:00PM Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nov 30, 2021 04:00PM Cytokinetics Announces Four Presentations at the 32nd International Symposium on ALS/MND
Nov 15, 2021 04:00PM Cytokinetics to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference
Nov 15, 2021 07:30AM Cytokinetics Announces Additional Results from GALACTIC-HF Presented at American Heart Association Scientific Sessions 2021  
Nov 8, 2021 04:00PM Cytokinetics Announces Two Presentations at the AHA Scientific Sessions 2021
Nov 3, 2021 04:00PM Cytokinetics Reports Third Quarter 2021 Financial Results
Nov 1, 2021 04:00PM Cytokinetics Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)
Oct 29, 2021 07:32AM Cytokinetics (CYTK) to Present Preclinical Data Relating to CK-3828136
Oct 29, 2021 07:30AM Cytokinetics Announces Preclinical Data Relating to CK-3828136 Presented at the 2021 Medicinal Chemistry Gordon Research Conference
Oct 21, 2021 04:00PM Cytokinetics Announces Preclinical Data for CK-3828136 to Be Presented at the 2021 Medicinal Chemistry Gordon Research Conference
Oct 20, 2021 04:00PM Cytokinetics to Announce Third Quarter Results on November 3, 2021
Oct 1, 2021 04:00PM Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sep 28, 2021 07:30AM Cytokinetics Announces Fourth Annual Communications Fellowship Grant Program Call for Proposals
Sep 23, 2021 04:00PM Cytokinetics to Host Analyst & Investor Day on October 7, 2021
Sep 13, 2021 05:55AM Cytokinetics (CYTK) Announces Results From REDWOOD-HCM and GALACTIC-HF Trials at the HFSA Annual Scientific Meeting
Sep 12, 2021 11:45AM Cytokinetics Announces Results From REDWOOD-HCM and GALACTIC-HF Presented in Late Breaking Clinical Trial Session at the HFSA Annual Scientific Meeting
Sep 8, 2021 04:00PM Cytokinetics to Participate in September Investor Conferences
Sep 7, 2021 07:30AM Cytokinetics to Host Investor Call and Webcast to Discuss the Full Results From Redwood-HCM at the HFSA Annual Scientific Meeting
Sep 1, 2021 04:00PM Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aug 31, 2021 07:30AM Cytokinetics Announces Results From REDWOOD-HCM and GALACTIC-HF to Be Presented in Late Breaking Clinical Trials Session at the HFSA Annual Scientific Meeting
Aug 19, 2021 07:30AM Cytokinetics and Cure SMA Renew Partnership to Advance Education and Awareness of SMA
Aug 5, 2021 04:00PM Cytokinetics Reports Second Quarter 2021 Financial Results
Aug 2, 2021 04:00PM Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aug 2, 2021 07:30AM Cytokinetics Announces Start of COURAGE-ALS, a Phase 3 Clinical Trial of Reldesemtiv in Patients With Amyotrophic Lateral Sclerosis
Jul 22, 2021 04:00PM Cytokinetics to Announce Second Quarter Results on August 5, 2021
Jul 19, 2021 07:37AM Cytokinetics (CYTK) Announces Positive Topline Results of Redwood-HCM
Jul 19, 2021 07:36AM Cytokinetics Announces Positive Topline Results of Redwood-HCM
Jul 1, 2021 04:00PM Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jun 30, 2021 07:30AM Cytokinetics (CYTK) Announces Additional Results From GALACTIC-HF Presented at the European Society of Cardiology Heart Failure 2021
Jun 30, 2021 07:30AM Cytokinetics Announces Additional Results From GALACTIC-HF Presented at the European Society of Cardiology Heart Failure 2021
Jun 23, 2021 07:30AM Cytokinetics Announces Three Presentations to Occur at the European Society of Cardiology Heart Failure 2021 Congress
Jun 15, 2021 07:30AM Cytokinetics Announces Completion of Enrollment in METEORIC-HF, The Second Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients With Heart Failure With Reduced Ejection Fraction
Jun 2, 2021 04:00PM Cytokinetics to Participate in Upcoming Investor Conferences
View More Recent Stories View Older Stories